Form 4: Innoviva Executive Matthew Ronsheim Reports Stock and Option Grants

Matthew Ronsheim, President of Innoviva Specialty Therapeutics, reports the acquisition of restricted stock units and non-statutory stock options in Innoviva, Inc.

Summary

• On March 5, 2024, Matthew Ronsheim, President of Innoviva Specialty Therapeutics, reported transactions involving Innoviva, Inc. securities.
• Ronsheim acquired 12,768 shares of common stock at a price of $14.88 per share through a restricted stock unit (RSU) grant.
• He also acquired 27,338 non-statutory stock options with an exercise price of $14.88.
• The RSU vests over time, with 25% vesting on February 20, 2025, and subsequent vesting in installments every three months thereafter, contingent upon continuous service.
• The options also vest over time, with 25% vesting on February 20, 2025, and the balance vesting in twelve substantially equal installments every three months thereafter, subject to continuous service.
• Accelerated vesting of the options may occur under certain change in control or termination scenarios.
• Following these transactions, Ronsheim directly owns 40,778 shares of Innoviva, Inc. common stock and 120,438 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the executive's continued contribution and the company's future prospects. The sentiment is neutral to positive.

Positives

• The grant of RSUs and stock options to a key executive aligns his interests with the long-term performance of the company.
• The vesting schedules incentivize continued service and commitment from the executive.
• Accelerated vesting provisions in change-in-control scenarios can provide stability during potential transitions.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Innoviva, Inc.'s stock.
• If Ronsheim's employment is terminated, unvested portions of the RSUs and options may be forfeited, unless specific change in control or termination conditions are met.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the RSUs and stock options suggest an expectation of continued service and contribution from the executive.

Industry Context

Stock option and RSU grants are common practices in the pharmaceutical and biotechnology industries to incentivize and retain key executives. These grants align executive compensation with shareholder value and company performance.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and terms described in the document appear to be consistent with industry norms for such grants.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.
• The grants have no immediate impact on customers, suppliers, or creditors.

Key Dates